.jpg)
Results Support Potential for STAR-0310 to be Best-in-Class OX40 Antagonist STAR-0310 Exhibits Longest-in-Class Half-Life of 68 Days and Cytokine Suppression Lasting At Least 20 Weeks After a Single 300 mg SC Injection, Supporting Potential Every-Six-Month Administration STAR-0310 Was Well-Tolerated, with no ADCC-Related Treatment-Emergent Adverse Events, Supporting a Wider Therapeutic Window with the Potential to Drive Greater Efficacy than First-Generation OX40 Antibodies
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, announced positive initial results from the Phase 1a trial of STAR-0310, a YTE half-life extended monoclonal antibody antagonist of OX40, in healthy subjects. STAR-0310 demonstrated a best-in-class half-life of up to 68 days, consistent with administration every six months, durable cytokine inhibition, and was well-tolerated with no antibody-dependent cellular cytotoxicity (ADCC)-related side effects. Based on these results, STAR-0310 has the potential to be the best-in-class OX40 antagonist.
Dr. Stephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, presented these results in a late-breaking oral presentation titled “Demonstration of Early Proof-of-Concept for STAR-0310, a Long-Acting OX40 Receptor Antagonist: Initial Safety, PK, and PD Results from a Phase 1a Trial” at 4:00pm CEST on 18 September in the Paris Nord room at the European Academy of Dermatology and Venereology Congress.
The Phase 1a healthy participant initial results of STAR-0310 demonstrate a compelling early differentiation story for the program. Importantly, we observed no fever and chills while seeing rapid and sustained target engagement and durable pharmacodynamic effects, demonstrating that STAR-0310 has the potential to drive greater efficacy without dose-limiting ADCC-related side effects seen in first-generation OX40 antagonists. Additionally, based on these Phase 1a results, STAR-0310’s half-life is the longest of any investigational OX40/OX40L antibody, supporting the potential for infrequent, every six-month administration with a low treatment burden. We believe that STAR-0310 could have a wider therapeutic window than other OX40 therapies that could potentially drive differentiated lasting efficacy for people living with atopic dermatitis, particularly the significant portion of patients who do not respond to existing biologics like Dupixent.
said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics.
STAR-0310 exhibited dose-proportional increases in concentrations, with slow clearance and an extended half-life of up to 68 days.
STAR-0310 was observed to be well-tolerated at all dose levels, with no serious treatment-emergent adverse events (TEAEs) or discontinuations. Mild, treatment-related TEAEs were observed in seven participants receiving STAR-0310 that resolved without intervention. No fever or chills were observed, consistent with the preclinical observation that STAR-0310 exhibits low ADCC activity.
Biomarker results showed that a single, subcutaneous injection of STAR-0310 resulted in sustained and durable ex vivo cytokine inhibition (IL-2, IL-22, IL-31, IL-4) for the duration of the observation period of 16 to 20 weeks, supporting robust target engagement and suggesting that STAR-0310 is modulating a broad spectrum of immune pathways beyond Th-2 for a long duration of effect, and could benefit a broader patient population than existing approved biologics.
The Phase 1a trial of STAR-0310 is a randomized, double-blind, placebo-controlled single ascending dose trial evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in 32 adults. Participants were randomized to receive a single subcutaneous dose of STAR-0310 or placebo across four dose cohorts: 150 mg, 300 mg, 600 mg, and 1200 mg. This interim analysis includes available safety, PK and PD data from all cohorts through the following follow-up windows: Day 168 for Cohort 1 (150 mg), Day 140 for Cohort 2 (300 mg), Day 112 for Cohort 3 (600 mg), and Day 84 for Cohort 4 (1200 mg). The Company plans to share an update on plans for STAR-0310’s development in the coming months.
For more information, read the original press release.
For more news from the world of long-acting therapeutics, sign up to the CELT's LONGEVITY mailing list here for regular updates.